2023 Chinese expert consensus on the impact of COVID-19 on the management of cardiovascular diseases

[1]  Xinxin Zhang,et al.  Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in Chinese mainland , 2023, Frontiers of Medicine.

[2]  H. Kiaris,et al.  The SARS-CoV-2 Spike protein induces long-term transcriptional perturbations of mitochondrial metabolic genes, causes cardiac fibrosis, and reduces myocardial contractile in obese mice , 2023, bioRxiv.

[3]  Matthew A. Wiles,et al.  Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. , 2022, JAMA.

[4]  K. Khunti,et al.  The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis , 2022, eClinicalMedicine.

[5]  F. Kirchhoff,et al.  Strong attenuation of SARS-CoV-2 Omicron BA.1 and increased replication of the BA.5 subvariant in human cardiomyocytes , 2022, Signal transduction and targeted therapy.

[6]  M. Jiménez-Navarro,et al.  Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination , 2022, Journal of clinical medicine.

[7]  Colin Simpson,et al.  Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales , 2022, The Lancet.

[8]  P. Sax,et al.  Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19 , 2022, Journal of the American College of Cardiology.

[9]  D. Zeng,et al.  Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes. , 2022, JAMA.

[10]  R. Likić,et al.  Intravenous immunoglobulin (IVIg) therapy in hospitalised adult COVID‐19 patients: A systematic review and meta‐analysis , 2022, Reviews in medical virology.

[11]  Lisa E. Gralinski,et al.  Understanding COVID-19-associated coagulopathy , 2022, Nature Reviews Immunology.

[12]  S. Sidik.  Heart disease after COVID: what the data say , 2022, Nature.

[13]  C. Samama,et al.  ISTH guidelines for antithrombotic treatment in COVID‐19 , 2022, Journal of Thrombosis and Haemostasis.

[14]  Chenyu Sun,et al.  Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis , 2022, European Journal of Clinical Pharmacology.

[15]  C. Giannattasio,et al.  Prevalence, Characteristics, and Outcomes of COVID-19–Associated Acute Myocarditis , 2022, Circulation.

[16]  S. D. de Ferranti,et al.  SARS-CoV-2 Infection and Associated Cardiovascular Manifestations and Complications in Children and Young Adults: A Scientific Statement From the American Heart Association , 2022, Circulation.

[17]  Xiaoping Zhou,et al.  [Mechanical circulatory support combined with immunomodulation treatment for patients with fulminant myocarditis: a single-center real-world study]. , 2022, Zhonghua xin xue guan bing za zhi.

[18]  Matthew W. Martinez,et al.  2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play , 2022, Journal of the American College of Cardiology.

[19]  M. Baniecki,et al.  Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.

[20]  E. Wan,et al.  Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine , 2022, Annals of Internal Medicine.

[21]  Md. Monowarul Islam,et al.  The Effects of the SARS-CoV-2 Virus on the Cardiovascular System and Coagulation State Leading to Cardiovascular Diseases: A Narrative Review , 2022, Inquiry : a journal of medical care organization, provision and financing.

[22]  OUP accepted manuscript , 2022, American Journal of Hypertension.

[23]  J. Butterton,et al.  Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.

[24]  H. Sørensen,et al.  SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study , 2021, BMJ.

[25]  K. Khunti,et al.  Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection , 2021, Nature Medicine.

[26]  Bin Liu,et al.  Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients , 2021, Signal Transduction and Targeted Therapy.

[27]  G. Hindricks,et al.  ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up , 2021, European heart journal.

[28]  B. Rohaut,et al.  Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial , 2021, The Lancet Respiratory Medicine.

[29]  C. Lavalle,et al.  Prevalence and Clinical Implications of COVID-19 Myocarditis , 2021, Cardiac Electrophysiology Clinics.

[30]  P. Ridker,et al.  Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. , 2021, JAMA.

[31]  R. Balicer,et al.  Myocarditis after Covid-19 Vaccination in a Large Health Care Organization , 2021, The New England journal of medicine.

[32]  Manfred S. Green,et al.  Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel , 2021, The New England journal of medicine.

[33]  J. Wisnivesky,et al.  Assessment of Cognitive Function in Patients After COVID-19 Infection , 2021, JAMA network open.

[34]  Antonio P. DeRosa,et al.  COVID-19 associated myocarditis: A systematic review , 2021, The American Journal of Emergency Medicine.

[35]  P. Hotez,et al.  Myocarditis With COVID-19 mRNA Vaccines , 2021, Circulation.

[36]  J. Gargano,et al.  Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[37]  J. Nielsen,et al.  Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19 , 2021, Advanced science.

[38]  X. Bian,et al.  A cohort autopsy study defines COVID-19 systemic pathogenesis , 2021, Cell Research.

[39]  G. Lip,et al.  Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews , 2021, European heart journal. Quality of care & clinical outcomes.

[40]  C. Esopenko,et al.  Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection , 2021, JAMA cardiology.

[41]  C. Giannattasio,et al.  Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab , 2021, European journal of heart failure.

[42]  Manesh R. Patel,et al.  SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes , 2021, Circulation.

[43]  G. Finocchiaro,et al.  COVID-19 and myocarditis: a systematic review and overview of current challenges , 2021, Heart Failure Reviews.

[44]  Allen K. Sills,et al.  Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening. , 2021, JAMA cardiology.

[45]  M. Diamond,et al.  SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis , 2021, JACC: Basic to Translational Science.

[46]  I. Douglas,et al.  Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia , 2021, The New England journal of medicine.

[47]  C. Granger,et al.  Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[48]  A. Mcgregor,et al.  Returning to physical activity after covid-19 , 2021, BMJ.

[49]  T. Chang,et al.  Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial , 2021, The Lancet Respiratory Medicine.

[50]  Jingwei Duan,et al.  Short-Term Efficacy and Safety of Different Mechanical Hemodynamic Support Devices for Cardiogenic Shock or High-Risk Pci: a Network Meta-Analysis of Thirty-Seven Trials. , 2021, Shock.

[51]  OUP accepted manuscript , 2021, European Heart Journal.

[52]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[53]  C. Mummery,et al.  Using Cardiovascular Cells from Human Pluripotent Stem Cells for COVID-19 Research: Why the Heart Fails , 2020, Stem Cell Reports.

[54]  Armando Pérez de Prado,et al.  In-hospital outcomes of patients with ST-segment elevation myocardial infarction and COVID-19. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[55]  L. Cooper,et al.  Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy , 2020, Circulation. Heart failure.

[56]  B. Levine,et al.  Coronavirus Disease 2019 and the Athletic Heart: Emerging Perspectives on Pathology, Risks, and Return to Play. , 2020, JAMA cardiology.

[57]  S. Heymans,et al.  Myocarditis and inflammatory cardiomyopathy: current evidence and future directions , 2020, Nature Reviews Cardiology.

[58]  S. Markowitz,et al.  Arrhythmic Complications of Patients Hospitalized With COVID-19 , 2020, Circulation. Arrhythmia and electrophysiology.

[59]  P. Saldiva,et al.  SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology , 2020, The Journal of experimental medicine.

[60]  M. Mazzeffi,et al.  COVID-19 Associated Hypercoagulability: Manifestations, Mechanisms, and Management , 2020, Shock.

[61]  F. Haddad,et al.  Cardiorespiratory considerations for return-to-play in elite athletes after COVID-19 infection: a practical guide for sport and exercise medicine physicians , 2020, British Journal of Sports Medicine.

[62]  A. Borobia,et al.  Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications , 2020, European journal of heart failure.

[63]  A. Silverio,et al.  Clinical characteristics and prognosis of hospitalized COVID‐19 patients with incident sustained tachyarrhythmias: A multicenter observational study , 2020, European journal of clinical investigation.

[64]  Yadong Gao.  COVID-19: Risk factors for critical illness , 2020, EClinicalMedicine.

[65]  R. V. Vander Heide,et al.  Cardiac Endotheliitis and Multisystem Inflammatory Syndrome After COVID-19 , 2020, Annals of Internal Medicine.

[66]  P. Kirchhof,et al.  Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. , 2020, JAMA cardiology.

[67]  J. Q. Brown,et al.  Unexpected Features of Cardiac Pathology in COVID-19 Infection. , 2020, Circulation.

[68]  K. Bhaskaran,et al.  OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.

[69]  W. Chung,et al.  SARS-CoV-2 Infection in Patients with Down Syndrome, Congenital Heart Disease, and Pulmonary Hypertension: Is Down Syndrome a Risk Factor? , 2020, The Journal of Pediatrics.

[70]  G. Ligabue,et al.  Cardiac Magnetic Resonance Characterization of Myocarditis-Like Acute Cardiac Syndrome in COVID-19 , 2020, JACC: Cardiovascular Imaging.

[71]  Robert A. Campbell,et al.  Platelet gene expression and function in patients with COVID-19 , 2020, Blood.

[72]  B. Brott,et al.  Stress-Induced Cardiomyopathy Precipitated by COVID-19 and Influenza A Coinfection , 2020, JACC: Case Reports.

[73]  Xiang Zhou,et al.  Outcomes of VA-ECMO with and without Left Centricular (LV) Decompression Using Intra-Aortic Balloon Pumping (IABP) versus Other LV Decompression Techniques: A Systematic Review and Meta-Analysis , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[74]  A. Frangakis,et al.  SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes , 2020, bioRxiv.

[75]  G. Kay,et al.  Atrial Arrhythmias in COVID-19 Patients , 2020, JACC: Clinical Electrophysiology.

[76]  R. Claus,et al.  Postmortem Examination of Patients With COVID-19. , 2020, JAMA.

[77]  G. Sayer,et al.  Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019. , 2020, JAMA cardiology.

[78]  D. Phelan,et al.  A Game Plan for the Resumption of Sport and Exercise After Coronavirus Disease 2019 (COVID-19) Infection. , 2020, JAMA cardiology.

[79]  P. Ponikowski,et al.  Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors , 2020, European heart journal.

[80]  V. Fuster,et al.  Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[81]  Thomas J Oxley,et al.  Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young , 2020, The New England journal of medicine.

[82]  R. Bush,et al.  Acute limb ischemia in patients with COVID-19 pneumonia , 2020, Journal of Vascular Surgery.

[83]  Hangyuan Guo,et al.  Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis , 2020, Journal of Infection.

[84]  S. Susen,et al.  Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence. , 2020, Circulation.

[85]  Yaolong Chen,et al.  Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines , 2020, Thrombosis and Haemostasis.

[86]  Marc A Pfeffer,et al.  Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.

[87]  Zhiyong Wu,et al.  Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: A descriptive survey report , 2020, The Journal of Heart and Lung Transplantation.

[88]  Allan Schwartz,et al.  COVID-19 and Cardiovascular Disease , 2020, Circulation.

[89]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[90]  S. Sinha,et al.  Percutaneous Impella RP use for refractory right heart failure in adolescents and young adults—A multicenter U.S. experience , 2020, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[91]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[92]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[93]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[94]  Marco Valgimigli,et al.  2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. , 2019, European heart journal.

[95]  Kristian Thygesen,et al.  Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Journal of the American College of Cardiology.

[96]  P. Reitsma,et al.  Pulmonary embolism , 2018, Nature Reviews Disease Primers.

[97]  Junbiao Chang,et al.  Effects of the antiretroviral drug 2'-deoxy-2'-β-fluoro-4'-azidocytidine (FNC) on P-gp, MRP2 and BCRP expressions and functions. , 2018, Pharmazie.

[98]  D. Teachey,et al.  Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia , 2017, Critical care medicine.

[99]  Akshay S. Desai,et al.  Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction , 2017, Journal of the American Heart Association.

[100]  B. Maron,et al.  Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 14: Sickle Cell Trait: A Scientific Statement From the American Heart Association and American College of Cardiology. , 2015, Journal of the American College of Cardiology.

[101]  M. Link,et al.  Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Associat , 2015, Journal of the American College of Cardiology.

[102]  Sandeep Sagar,et al.  Myocarditis , 2012, The Lancet.